# Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

> **NCT05783596** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Reid Merryman, MD** · enrollment: 47 (actual)

## Conditions studied

- Follicular Lymphoma
- Marginal Zone Lymphoma
- Indolent Non-hodgkin Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Glofitamab

## Key facts

- **NCT ID:** NCT05783596
- **Lead sponsor:** Reid Merryman, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-18
- **Primary completion:** 2026-08
- **Final completion:** 2029-08
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05783596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05783596, "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-08-10 from https://api.ai-analytics.org/clinical/NCT05783596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*